--- title: "Adma Biologics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 114.49 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285476736.md" datetime: "2026-05-07T03:08:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285476736.md) - [en](https://longbridge.com/en/news/285476736.md) - [zh-HK](https://longbridge.com/zh-HK/news/285476736.md) --- # Adma Biologics | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 114.49 M Revenue: As of FY2026 Q1, the actual value is USD 114.49 M, missing the estimate of USD 139.97 M. EPS: As of FY2026 Q1, the actual value is USD 0.19, missing the estimate of USD 0.1933. EBIT: As of FY2026 Q1, the actual value is USD 59.28 M. #### Revenue - **Total Revenue**: ADMA Biologics, Inc. reported total revenue of $114.5 million for the first quarter of 2026, which was flat year-over-year compared to $114.8 million in the first quarter of 2025. - **ASCENIV Revenue**: ASCENIV revenue was $97.5 million, representing a 28% year-over-year growth. - **BIVIGAM Revenue**: BIVIGAM revenue declined by 54% year-over-year to $15.4 million. - **Intermediates and other products Revenue**: Revenue from intermediates and other products decreased by $3.0 million year-over-year, reaching $0.833 million in Q1 2026 from $3.872 million in Q1 2025, a -78.5% decline. - **ADMA BioManufacturing Revenue**: This segment reported $113.741 million in revenue for Q1 2026, nearly flat compared to $113.716 million in Q1 2025. - **Plasma Collection Centers Revenue**: Revenue from Plasma Collection Centers was $0.716 million, a -31.8% decrease from $1.050 million in Q1 2025. - **License Revenue**: License revenue remained flat at $0.036 million year-over-year. #### Profitability - **Gross Profit**: Gross profit for the quarter was $80.8 million, an increase from $61.1 million in the prior-year period. - **Gross Margin**: The company achieved a gross margin of 71% in the first quarter of 2026, up from 53% in the prior-year period. - **GAAP Net Income**: GAAP net income was $45.3 million, a 68% year-over-year growth compared to $26.9 million in the first quarter of 2025. - **Adjusted Net Income**: Adjusted Net Income grew 22% year-over-year to $40.7 million in Q1 2026, from $33.299 million in Q1 2025. - **Adjusted EBITDA**: Adjusted EBITDA increased 24% year-over-year to $59.7 million in Q1 2026, from $47.939 million in Q1 2025. - **Income from Operations**: Income from operations was $58.274 million in Q1 2026, up from $34.881 million in Q1 2025. #### Operating Expenses - **Research and development expenses**: Research and development expenses increased to $2.6 million from $0.8 million in the prior-year period, primarily due to investments in the SG-001 development project. - **Selling, general and administrative expenses**: Selling, general and administrative expenses were $26.7 million, up from $24.1 million in the prior-year period, mainly due to higher employee-related costs. - **Gain on sale of plasma centers**: The company recognized a gain of $7.980 million from the sale of plasma centers in Q1 2026. #### Cash Flow - **Cash from Operations**: Cash from operations was $58 million for the first quarter of 2026, highlighting strong cash generation. #### Other Key Metrics - **Net Leverage**: ADMA Biologics, Inc. exited the first quarter of 2026 with net leverage below 0.5x. - **Share Repurchases**: The company converted approximately 3.7% of its outstanding share count into treasury stock through its Accelerated Share Repurchase (ASR) program and Rule 10b5-1 trading plan through March 31, 2026. - **SG-001 Market Opportunity**: The investigational hyperimmune globulin program, SG-001, is positioned for a potentially rapid commercial ramp-up toward an approximately $300 million to $500 million annual market opportunity, if approved. #### Outlook / Guidance ADMA Biologics, Inc. updated its financial outlook for fiscal year 2026, projecting total revenue between $530 million and $560 million, Adjusted Net Income between $170 million and $200 million, and Adjusted EBITDA between $265 million and $300 million. The company withdrew its previously provided long-term guidance due to evolving competitive dynamics in the U.S. plasma products and immunoglobulin (IG) market, though the growth outlook for ASCENIV remains strong. ### Related Stocks - [ADMA.US](https://longbridge.com/en/quote/ADMA.US.md) ## Related News & Research - [17:28 ETRosen Law Firm Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMA](https://longbridge.com/en/news/286821593.md) - [20:15 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA](https://longbridge.com/en/news/286483885.md) - [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md)